{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030824","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.900224+00:00","generated_at":"2026-05-25T17:35:26.727440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD","bullets":["Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.","Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.","Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.","Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.","ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030824","json":"https://secwatch.observer/filing/0000950170-25-030824.json","markdown":"https://secwatch.observer/filing/0000950170-25-030824.md","text":"https://secwatch.observer/filing/0000950170-25-030824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/0000950170-25-030824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/annx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:35:26.727440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}